All BNF sections

Search for a BNF section by name or code, and get trends for total prescribing.

• 1: Gastro-Intestinal System
•    1.1: Dyspepsia and gastro-oesophageal reflux disease
•       1.1.1: Antacids and simeticone
•       1.1.1.0: Antacids and simeticone
•       1.1.1.2: Sodium bicarbonate
•       1.1.2: Compound alginates and proprietary indigestion preparations
•       1.1.2.1: Compound Alginates and proprietary indigestion preparations
•    1.2: Antispasmodics and other drugs altering gut motility
•    1.3: Antisecretory drugs and mucosal protectants
•       1.3.1: H2-receptor antagonists
•       1.3.1.0: H2-Receptor antagonists
•       1.3.2: Selective antimuscarinics
•       1.3.2.0: Selective antimuscarinics
•       1.3.3: Chelates and complexes
•       1.3.3.0: Chelates and complexes
•       1.3.4: Prostaglandin analogues
•       1.3.4.0: Prostaglandin analogues
•       1.3.5: Proton pump inhibitors
•       1.3.5.0: Proton pump inhibitors
•    1.4: Acute diarrhoea
•       1.4.1: Adsorbents and bulk-forming drugs
•       1.4.1.0: Adsorbents and bulk-forming drugs
•       1.4.2: Antimotility drugs
•       1.4.2.0: Antimotility drugs
•       1.4.3: Enkephalinase inhibitors
•       1.4.3.0: Enkephalinase inhibitors
•       1.4.4: Tryptophan hydroxylase inhibitors
•       1.4.4.0: Tryptophan hydroxylase inhibitors
•    1.5: Chronic bowel disorders
•       1.5.1: Aminosalicylates
•       1.5.1.0: Aminosalicylates
•       1.5.2: Corticosteroids
•       1.5.2.0: Corticosteroids
•       1.5.3: Drugs affecting immune response
•       1.5.3.0: Drugs affecting immune response
•       1.5.4: Food allergy
•       1.5.4.0: Food allergy
•    1.6: Laxatives
•       1.6.1: Bulk-forming laxatives
•       1.6.1.0: Bulk-forming laxatives
•       1.6.2: Stimulant laxatives
•       1.6.2.0: Stimulant laxatives
•       1.6.3: Faecal softeners
•       1.6.3.0: Faecal softeners
•       1.6.4: Osmotic laxatives
•       1.6.4.0: Osmotic laxatives
•       1.6.5: Bowel cleansing preparations
•       1.6.5.0: Bowel cleansing preparations
•       1.6.6: Peripheral opioid-receptor antagonists
•       1.6.6.0: Peripheral opioid-receptor antagonists
•       1.6.7: Other drugs used in constipation
•       1.6.7.0: Other drugs used in constipation
•    1.7: Local preparations for anal and rectal disorders
•       1.7.1: Soothing haemorrhoidal preparations
•       1.7.1.0: Soothing haemorrhoidal preparations
•       1.7.2: Copound haemorrhoidal preparations with corticosteroid
•       1.7.2.0: Copound haemorrhoidal preparations with corticosteroid
•       1.7.3: Rectal sclerosants
•       1.7.3.0: Rectal sclerosants
•       1.7.4: Management of anal fissures
•       1.7.4.0: Management of anal fissures
•    1.8: Stoma care
•       1.8.1: Local care of stoma
•       1.8.1.0: Local care of stoma
•    1.9: Drugs affecting intestinal secretions
•       1.9.1: Drugs affecting biliary composition and flow
•       1.9.1.0: Drugs affecting biliary composition and flow
•       1.9.4: Pancreatin
•       1.9.4.0: Pancreatin
• 2: Cardiovascular System
•    2.1: Positive inotropic drugs
•       2.1.1: Cardiac glycosides
•       2.1.1.0: Cardiac glycosides
•       2.1.2: Phosphodiesterase Type-3 inhibitors
•       2.1.2.0: Phosphodiesterase Type-3 inhibitors
•    2.2: Diuretics
•       2.2.1: Thiazides and related diuretics
•       2.2.1.0: Thiazides and related diuretics
•       2.2.2: Loop diuretics
•       2.2.2.0: Loop diuretics
•       2.2.3: Potassium-sparing diuretics and aldosterone antagonists
•       2.2.3.0: Potassium-sparing diuretics and aldosterone antagonists
•       2.2.4: Potassium sparing diuretics and compounds
•       2.2.4.0: Potassium sparing diuretics and compounds
•       2.2.5: Osmotic diuretics
•       2.2.5.0: Osmotic diuretics
•       2.2.8: Diuretics with potassium
•       2.2.8.0: Diuretics with potassium
•    2.3: Anti-arrhythmic drugs
•       2.3.2: Drugs for arrhythmias
•       2.3.2.0: Drugs for arrhythmias
•    2.4: Beta-adrenoceptor blocking drugs
•    2.5: Hypertension and heart failure
•       2.5.1: Vasodilator antihypertensive drugs
•       2.5.1.0: Vasodilator antihypertensive drugs
•       2.5.2: Centrally-acting antihypertensive drugs
•       2.5.2.0: Centrally-acting antihypertensive drugs
•       2.5.3: Adrenergic neurone blocking drugs
•       2.5.3.0: Adrenergic neurone blocking drugs
•       2.5.4: Alpha-adrenoceptor blocking drugs
•       2.5.4.0: Alpha-adrenoceptor blocking drugs
•       2.5.5: Renin-angiotensin system drugs
•       2.5.5.1: Angiotensin-converting enzyme inhibitors
•       2.5.5.2: Angiotensin-II receptor antagonists
•       2.5.5.3: Renin inhibitors
•       2.5.8: Other adrenergic neurone blocking drugs
•       2.5.8.0: Other adrenergic neurone blocking drugs
•    2.6: Nitrates, calcium-channel blockers & other antianginal drugs
•       2.6.1: Nitrates
•       2.6.1.0: Nitrates
•       2.6.2: Calcium-channel blockers
•       2.6.2.0: Calcium-channel blockers
•       2.6.3: Other antianginal drugs
•       2.6.3.0: Other antianginal drugs
•       2.6.4: Peripheral vasodilators and related drugs
•       2.6.4.0: Peripheral vasodilators and related drugs
•    2.7: Sympathomimetics and other vasoconstrictor drugs
•       2.7.1: Inotropic sympathomimetics
•       2.7.1.0: Inotropic sympathomimetics
•       2.7.2: Vasoconstrictor sympathomimetics
•       2.7.2.0: Vasoconstrictor sympathomimetics
•       2.7.3: Cardiopulmonary resuscitation
•       2.7.3.0: Cardiopulmonary resuscitation
•    2.8: Anticoagulants and protamine
•       2.8.1: Parenteral anticoagulants
•       2.8.1.0: Parenteral anticoagulants
•       2.8.2: Oral anticoagulants
•       2.8.2.0: Oral anticoagulants
•       2.8.3: Protamine sulfate
•       2.8.3.0: Protamine sulfate
•    2.9: Antiplatelet drugs
•    2.10: Stable angina, acute coronary syndromes and fibrinolysis
•       2.10.2: Fibrinolytic drugs
•       2.10.2.0: Fibrinolytic drugs
•    2.11: Antifibrinolytic drugs and haemostatics
•    2.12: Lipid-regulating drugs
•    2.13: Local sclerosants
• 3: Respiratory System
•    3.1: Bronchodilators
•       3.1.1: Adrenoceptor agonists
•       3.1.1.1: Selective beta(2)-agonists
•       3.1.1.2: Other andrenoceptor agonists
•       3.1.2: Antimuscarinic bronchodilators
•       3.1.2.0: Antimuscarinic bronchodilators
•       3.1.3: Theophylline
•       3.1.3.0: Theophylline
•       3.1.4: Compound bronchodilator preparations
•       3.1.4.0: Compound bronchodilator preparations
•    3.2: Corticosteroids (respiratory)
•    3.3: Cromoglycate, leukotriene and phosphodesterase type-4 inhib
•       3.3.1: Cromoglycate and related therapy
•       3.3.1.0: Cromoglycate and related therapy
•       3.3.2: Leukotriene receptor antagonists
•       3.3.2.0: Leukotriene receptor antagonists
•       3.3.3: Phosphodiesterase Type-4 inhibitors
•       3.3.3.0: Phosphodiesterase Type-4 inhibitors
•    3.4: Antihistamines, hyposensitisation and allergic emergencies
•       3.4.1: Antihistamines
•       3.4.1.0: Antihistamines
•       3.4.2: Allergen immunotherapy
•       3.4.2.0: Allergen immunotherapy
•       3.4.3: Allergic emergencies
•       3.4.3.0: Allergic emergencies
•    3.5: Respiratory stimulants and pulmonary surfactants
•       3.5.1: Respiratory stimulants
•       3.5.1.0: Respiratory stimulants
•    3.6: Oxygen
•    3.7: Mucolytics
•    3.8: Aromatic inhalations
•    3.9: Cough preparations
•       3.9.1: Cough suppressants
•       3.9.1.0: Cough suppressants
•       3.9.2: Expectorant and demulcent cough preparations
•       3.9.2.0: Expectorant and demulcent cough preparations
•    3.10: Systemic nasal decongestants
•    3.11: Antifibrotics
•       3.11.1: Antifibrotics
•       3.11.1.0: Antifibrotics
• 4: Central Nervous System
•    4.1: Hypnotics and anxiolytics
•       4.1.1: Hypnotics
•       4.1.1.0: Hypnotics
•       4.1.2: Anxiolytics
•       4.1.2.0: Anxiolytics
•       4.1.3: Barbiturates
•       4.1.3.0: Barbiturates
•       4.1.4: Other hypnotics and anxiolytics
•       4.1.4.0: Other hypnotics and anxiolytics
•    4.2: Drugs used in psychoses and related disorders
•       4.2.1: Antipsychotic drugs
•       4.2.1.0: Antipsychotic drugs
•       4.2.2: Antipsychotic depot injections
•       4.2.2.0: Antipsychotic depot injections
•       4.2.3: Drugs used for mania and hypomania
•       4.2.3.0: Drugs used for mania and hypomania
•    4.3: Antidepressant drugs
•       4.3.1: Tricyclic and related antidepressant drugs
•       4.3.1.0: Tricyclic and related antidepressant drugs
•       4.3.2: Monoamine-oxidase inhibitors (maois)
•       4.3.2.0: Monoamine-oxidase inhibitors (maois)
•       4.3.3: Selective serotonin re-uptake inhibitors
•       4.3.3.0: Selective serotonin re-uptake inhibitors
•       4.3.4: Other antidepressant drugs
•       4.3.4.0: Other antidepressant drugs
•    4.4: CNS stimulants and drugs used for ADHD
•    4.5: Drugs used in the treatment of obesity
•       4.5.1: Gastro-intestinal anti-obesity drugs
•       4.5.1.0: Gastro-intestinal anti-obesity drugs
•       4.5.2: Centrally-acting appetite suppressants
•       4.5.2.0: Centrally-acting appetite suppressants
•    4.6: Drugs used in nausea and vertigo
•    4.7: Analgesics
•       4.7.1: Non-opioid analgesics and compound preparations
•       4.7.1.0: Non-opioid analgesics and compound preparations
•       4.7.2: Opioid analgesics
•       4.7.2.0: Opioid analgesics
•       4.7.3: Neuropathic pain
•       4.7.3.0: Neuropathic pain
•       4.7.4: Antimigraine drugs
•       4.7.4.1: Treatment of acute migraine
•       4.7.4.2: Prophylaxis of migraine
•    4.8: Antiepileptic drugs
•       4.8.1: Control of epilepsy
•       4.8.1.0: Control of epilepsy
•       4.8.2: Drugs used in status epilepticus
•       4.8.2.0: Drugs used in status epilepticus
•    4.9: Drugs used in parkinsonism and related disorders
•       4.9.1: Dopaminergic drugs used in parkinsonism
•       4.9.1.0: Dopaminergic drugs used in parkinsonism
•       4.9.2: Antimuscarinic drugs used in parkinsonism
•       4.9.2.0: Antimuscarinic drugs used in parkinsonism
•       4.9.3: Essential tremor,chorea,tics and related disorders
•       4.9.3.0: Essential tremor,chorea,tics and related disorders
•    4.10: Drugs used in substance dependence
•       4.10.1: Alcohol dependence
•       4.10.1.0: Alcohol dependence
•       4.10.2: Nicotine dependence
•       4.10.2.0: Nicotine dependence
•       4.10.3: Opioid dependence
•       4.10.3.0: Opioid dependence
•    4.11: Drugs for dementia
• 5: Infections
•    5.1: Antibacterial drugs
•       5.1.1: Penicillins
•       5.1.1.1: Benzylpenicillin and phenoxymethylpenicillin
•       5.1.1.2: Penicillinase-resistant penicillins
•       5.1.1.3: Broad-spectrum penicillins
•       5.1.1.4: Antipseudomonal penicillins
•       5.1.1.5: Mecillinams
•       5.1.2: Cephalosporins and other beta-lactams
•       5.1.2.0: Cephalosporins and other beta-lactams
•       5.1.2.1: Cephalosporins
•       5.1.2.2: Carbapenems
•       5.1.2.3: Other beta-lactam antibiotics
•       5.1.3: Tetracyclines
•       5.1.3.0: Tetracyclines
•       5.1.4: Aminoglycosides
•       5.1.4.0: Aminoglycosides
•       5.1.5: Macrolides
•       5.1.5.0: Macrolides
•       5.1.6: Clindamycin and lincomycin
•       5.1.6.0: Clindamycin and lincomycin
•       5.1.7: Some other antibacterials
•       5.1.7.0: Some other antibacterials
•       5.1.8: Sulfonamides and trimethoprim
•       5.1.8.0: Sulfonamides and trimethoprim
•       5.1.9: Antituberculosis drugs
•       5.1.9.0: Antituberculosis drugs
•       5.1.10: Antileprotic drugs
•       5.1.11: Metronidazole, tinidazole and ornidazole
•       5.1.11.0: Metronidazole, tinidazole and ornidazole
•       5.1.12: Quinolones
•       5.1.12.0: Quinolones
•       5.1.13: Urinary-tract infections
•       5.1.13.0: Urinary-tract infections
•    5.2: Antifungal drugs
•       5.2.1: Triazole antifungals
•       5.2.1.0: Triazole antifungals
•       5.2.2: Imidazole antifungals
•       5.2.2.0: Imidazole antifungals
•       5.2.3: Polyene antifungals
•       5.2.3.0: Polyene antifungals
•       5.2.4: Echinocandin antifungals
•       5.2.4.0: Echinocandin antifungals
•       5.2.5: Other antifungals
•       5.2.5.0: Other antifungals
•    5.3: Antiviral drugs
•       5.3.1: HIV infection
•       5.3.1.0: HIV infection
•       5.3.2: Herpesvirus infections
•       5.3.2.1: Herpes simplex and varicella-zoster
•       5.3.2.2: Cytomegalovirus infection
•       5.3.3: Viral hepatitis
•       5.3.3.1: Chronic hepatitis B
•       5.3.3.2: Chronic hepatitis C
•       5.3.4: Influenza
•       5.3.4.0: Influenza
•       5.3.5: Respiratory syncytial virus
•       5.3.5.0: Respiratory syncytial virus
•       5.3.6: Coronavirus
•       5.3.6.0: Coronavirus
•    5.4: Antiprotozoal drugs
•       5.4.1: Antimalarials
•       5.4.1.0: Antimalarials
•       5.4.2: Amoebicides
•       5.4.2.0: Amoebicides
•       5.4.4: Antigiardial drugs
•       5.4.4.0: Antigiardial drugs
•       5.4.5: Leishmaniacides
•       5.4.5.0: Leishmaniacides
•       5.4.8: Drugs for pneumocystis pneumonia
•       5.4.8.0: Drugs for pneumocystis pneumonia
•    5.5: Anthelmintics
•       5.5.1: Drugs for threadworms
•       5.5.1.0: Drugs for threadworms
•       5.5.2: Ascaricides
•       5.5.2.0: Ascaricides
•       5.5.3: Drugs for tapeworm infections
•       5.5.3.0: Drugs for tapeworm infections
•       5.5.5: Schistosomicides
•       5.5.5.0: Schistosomicides
•       5.5.6: Filaricides
•       5.5.6.0: Filaricides
• 6: Endocrine System
•    6.1: Drugs used in diabetes
•       6.1.1: Insulin
•       6.1.1.1: Short-acting insulins
•       6.1.1.2: Intermediate and long-acting insulins
•       6.1.2: Antidiabetic drugs
•       6.1.2.1: Sulfonylureas
•       6.1.2.2: Biguanides
•       6.1.2.3: Other antidiabetic drugs
•       6.1.4: Treatment of hypoglycaemia
•       6.1.4.0: Treatment of hypoglycaemia
•       6.1.6: Diabetic diagnostic and monitoring agents
•       6.1.6.0: Diabetic diagnostic and monitoring agents
•    6.2: Thyroid and antithyroid drugs
•       6.2.1: Thyroid hormones
•       6.2.1.0: Thyroid hormones
•       6.2.2: Antithyroid drugs
•       6.2.2.0: Antithyroid drugs
•    6.3: Corticosteroids (endocrine)
•       6.3.1: Replacement therapy
•       6.3.1.0: Replacement therapy
•       6.3.2: Glucocorticoid therapy
•       6.3.2.0: Use of corticosteroids
•    6.4: Sex Hormones
•       6.4.1: Female sex hormones and their modulators
•       6.4.1.1: Oestrogens and Hormone Replacement Therapy
•       6.4.1.2: Progestogens and progesterone receptor modulators
•       6.4.2: Male sex hormones and antagonists
•       6.4.2.0: Male sex hormones and antagonists
•       6.4.3: Anabolic steroids
•       6.4.3.0: Anabolic steroids
•    6.5: Hypothalamic and pituitary hormones and anti, oestrogens
•       6.5.1: Hypothalamic & anterior pituitary hormone & antioestrogens
•       6.5.1.0: Hypothalamic & anterior pituitary hormone & antioestrogens
•       6.5.2: Posterior pituitary hormones and antagonists
•       6.5.2.0: Posterior pituitary hormones and antagonists
•    6.6: Drugs affecting bone metabolism
•       6.6.1: Calcitonin and parathyroid hormone
•       6.6.1.0: Calcitonin and parathyroid hormone
•       6.6.2: Bisphosphonates and other drugs
•       6.6.2.0: Bisphosphonates and other drugs
•    6.7: Other endocrine drugs
•       6.7.1: Bromocriptine and other dopaminergic drugs
•       6.7.1.0: Bromocriptine and other dopaminergic drugs
•       6.7.2: Drugs affecting gonadotrophins
•       6.7.2.0: Drugs affecting gonadotrophins
•       6.7.3: Metyrapone
•       6.7.3.0: Metyrapone
•       6.7.4: Somatomedins
•       6.7.4.0: Somatomedins
• 7: Obstetrics, Gynaecology and Urinary-Tract Disorders
•    7.1: Drugs used in obstetrics
•       7.1.1: Prostaglandins and oxytocics
•       7.1.1.0: Prostaglandins and oxytocics
•       7.1.1.1: Drugs affecting the ductus arteriosus
•       7.1.2: Mifepristone
•       7.1.2.1: Mifepristone and misoprostol
•       7.1.3: Myometrial relaxants
•       7.1.3.0: Myometrial relaxants
•    7.2: Treatment of vaginal and vulval conditions
•       7.2.1: Preparations for vaginal and vulval changes
•       7.2.1.0: Preparations for vaginal/vulval changes
•       7.2.2: Vaginal and vulval infections
•       7.2.2.0: Vaginal and vulval infections
•    7.3: Contraceptives
•       7.3.1: Combined hormonal contraceptives and systems
•       7.3.1.0: Combined hormonal contraceptives
•       7.3.1.1: Combined hormonal systems
•       7.3.2: Progestogen-only contraceptives
•       7.3.2.1: Oral progestogen-only contraceptives
•       7.3.2.2: Parenteral progestogen-only contraceptives
•       7.3.2.3: Intra-uterine progestogen-only device
•       7.3.3: Spermicidal contraceptives
•       7.3.3.0: Spermicidal contraceptives
•       7.3.5: Emergency contraception
•       7.3.5.0: Emergency contraception
•    7.4: Drugs for genito-urinary disorders
•       7.4.1: Drugs for urinary retention
•       7.4.1.0: Drugs for urinary retention
•       7.4.2: Drugs for urinary frequency enuresis and incontinence
•       7.4.2.0: Drugs for urinary frequency enuresis and incontinence
•       7.4.3: Drugs used in urological pain
•       7.4.3.0: Drugs used in urological pain
•       7.4.4: Bladder instillations and urological surgery
•       7.4.4.0: Bladder instillations/urological surgery
•       7.4.5: Drugs for erectile dysfunction
•       7.4.5.0: Drugs for erectile dysfunction
•       7.4.6: Drugs for premature ejaculation
•       7.4.6.0: Drugs for premature ejaculation
• 8: Malignant Disease and Immunosuppression
•    8.1: Cytotoxic drugs
•       8.1.1: Alkylating drugs
•       8.1.1.0: Alkylating drugs
•       8.1.2: Anthracyclines and cytotoxic antibiotics
•       8.1.2.0: Anthracyclines and cytotoxic antibiotics
•       8.1.3: Antimetabolites
•       8.1.3.0: Antimetabolites
•       8.1.4: Vinca alkaloids and etoposide
•       8.1.4.0: Vinca alkaloids and etoposide
•       8.1.5: Other antineoplastic drugs
•       8.1.5.0: Other antineoplastic drugs
•    8.2: Drugs affecting the immune response
•       8.2.1: Antiproliferative immunosuppressants
•       8.2.1.0: Antiproliferative immunosuppressants
•       8.2.2: Corticosteroids and other immunosuppressants
•       8.2.2.0: Corticosteroids and other immunosuppressants
•       8.2.3: Anti-lymphocyte monoclonal antibodies
•       8.2.3.0: Anti-lymphocyte monoclonal antibodies
•       8.2.4: Other immunomodulating drugs
•       8.2.4.0: Other immunomodulating drugs
•    8.3: Sex hormones and hormone antagonists in malignant disease
•       8.3.1: Oestrogens
•       8.3.1.0: Oestrogens
•       8.3.2: Progestogens
•       8.3.2.0: Progestogens
•       8.3.4: Hormone antagonists
•       8.3.4.1: Breast cancer
•       8.3.4.2: Prostate cancer and gonadorelin analogues
•       8.3.4.3: Somatostatin analogues
• 9: Nutrition and Blood
•    9.1: Anaemias and some other blood disorders
•       9.1.1: Iron-deficiency anaemias
•       9.1.1.1: Oral iron
•       9.1.1.2: Parenteral iron
•       9.1.2: Drugs used in megaloblastic anaemias
•       9.1.2.0: Drugs used in megaloblastic anaemias
•       9.1.3: Hypoplastic,haemolytic and renal anaemias
•       9.1.3.0: Hypoplastic/haemolytic and renal anaemias
•       9.1.4: Drugs used in platelet disorders
•       9.1.4.0: Drugs used in platelet disorders
•       9.1.6: Drugs used in neutropenia
•       9.1.6.0: Drugs used in neutropenia
•    9.2: Fluids and electrolytes
•       9.2.1: Oral preparation for fluid and electrolyte imbalance
•       9.2.1.1: Oral potassium
•       9.2.1.2: Oral sodium and water
•       9.2.1.3: Oral bicarbonate
•       9.2.2: Parent prepn for fluid and electrolyte imb
•       9.2.2.1: Electrolytes and water
•       9.2.2.2: Plasma and plasma substitutes
•    9.3: Intravenous nutrition
•    9.4: Oral nutrition (OLD - DO NOT USE)
•       9.4.1: Foods for special diets
•       9.4.1.0: Foods for special diets
•       9.4.2: Enteral nutrition
•       9.4.2.0: Enteral nutrition
•    9.5: Minerals
•       9.5.1: Calcium and magnesium
•       9.5.1.1: Calcium supplements
•       9.5.1.2: Hypercalcaemia
•       9.5.1.3: Magnesium
•       9.5.2: Phosphorus
•       9.5.2.1: Phosphate supplements
•       9.5.2.2: Phosphate binding agents
•       9.5.3: Fluoride
•       9.5.3.0: Fluoride
•       9.5.4: Zinc and other minerals
•       9.5.4.1: Zinc
•       9.5.4.2: Chromium
•       9.5.4.4: Kelp
•       9.5.4.7: Selenium
•       9.5.4.8: Other mineral formulations
•       9.5.5: Selenium
•       9.5.5.0: Selenium
•    9.6: Vitamins
•       9.6.1: Vitamin A
•       9.6.1.1: Vitamin A
•       9.6.1.2: Betacarotene
•       9.6.2: Vitamin B group
•       9.6.2.2: Nicotinamide (B3)
•       9.6.2.3: Pantothenic acid (Calcium Pantothenate)
•       9.6.2.4: Pyridoxine hydrochloride (B6)
•       9.6.2.5: Riboflavine (B2)
•       9.6.2.6: Thiamine hydrochloride (B1)
•       9.6.2.7: Vitamin B compound
•       9.6.2.8: Other vitamin B preparations
•       9.6.3: Vitamin C
•       9.6.3.1: Vitamin C (ascorbic acid)
•       9.6.3.3: Other vitamin C preparations
•       9.6.4: Vitamin D
•       9.6.4.0: Vitamin D
•       9.6.4.8: Other vitamin D preparations
•       9.6.5: Vitamin E
•       9.6.5.0: Vitamin E
•       9.6.6: Vitamin K
•       9.6.6.0: Vitamin K
•       9.6.7: Multivitamin preparations
•       9.6.7.0: Multivitamin preparations
•    9.7: Bitters and tonics
•    9.8: Metabolic disorders
•       9.8.1: Drugs used in metabolic disorders
•       9.8.1.0: Drugs used in metabolic disorders
•       9.8.2: Acute porphyrias
•       9.8.2.0: Acute porphyrias
•    9.9: Foods
•    9.10: Compound vitamin and mineral formulations
•    9.11: Health supplements
•       9.11.1: Amino acids and nutritional agents
•       9.11.1.0: Amino acids and nutritional agents
•       9.11.2: Enzymes
•       9.11.2.0: Enzymes
•       9.11.4: Digestive aids
•       9.11.4.0: Digestive aids
•    9.12: Other health supplements
•    9.13: Oral nutrition
•       9.13.1: ONS - Standard
•       9.13.1.1: Unable to meet nutritional needs using food alone (091301)
•       9.13.2: ONS - Standard (paed)
•       9.13.2.1: Unable to meet nutritional needs using food alone (091302)
•       9.13.3: ONS - Cancer specific
•       9.13.3.1: UtM nutritional needs using food alone + cancer (091303)
•       9.13.4: ONS - COPD specific
•       9.13.4.1: UtM nutritional needs using food alone + COPD (091304)
•       9.13.5: ONS - Dysphagia specific
•       9.13.5.1: UtM nutritional needs using food alone+dysphagia (091305)
•       9.13.6: ONS - Impaired GI function specific
•       9.13.6.1: UtM nutrit needs using food alone+imp GI func/malab (091306)
•       9.13.6.2: Induction of clinical remission in Crohns disease (091306)
•       9.13.8: ONS - Renal failure specific
•       9.13.8.1: UtM nutrit needs using food alone + renal failure (091308)
•       9.13.9: ONS - Condition specific (paed)
•       9.13.9.1: UtM nutrit needs using food alone+imp GI func/malab (091309)
•       9.13.9.2: UtM nutrit need ufa+ r/f+peritoneal rapid o/nt dialy(091309)
•       9.13.9.3: UtM nutrit needs using food alone + liver failure (091309)
•       9.13.9.4: UtM nutrit needs using food alone + renal failure (091309)
•       9.13.10: Infant formula - Condition specific
•       9.13.10.1: Cows milk protein allergy (091310)
•       9.13.10.2: Cows milk protein allergy + impaired GI func/malab (091310)
•       9.13.10.3: Cows milk p/aller+impaired GI func/malab+f/growth (091310)
•       9.13.10.4: Faltering growth (091310)
•       9.13.10.5: Lactose intolerance (091310)
•       9.13.10.6: Lactose intol, cows milk p/aller / galactosaemia (091310)
•       9.13.10.7: Severe cows milk p/aller or multiple food allergies (091310)
•       9.13.10.8: Significant reflux (091310)
•       9.13.10.9: Disorders of calcium metabolism (091310)
•       9.13.11: Infant formula - Premature
•       9.13.11.1: Infants born <34 w/gest+weight <2kg + not breastfed (091311)
•       9.13.12: Infant formula - Additive
•       9.13.12.1: Lactose intolerance (091312)
•       9.13.13: Infant follow on formula - Condition specific
•       9.13.13.1: Cows milk protein allergy + impaired GI func/malab (091313)
•       9.13.13.2: Cows milk protein allergy (091313)
•       9.13.14: Fortifier - Energy and protein
•       9.13.14.1: Additional energy & protein requirement (091314)
•       9.13.14.2: Additional energy requirement (091314)
•       9.13.15: Fortifier - Fibre
•       9.13.15.1: Additional fibre requirement (091315)
•       9.13.16: Thickener
•       9.13.16.1: Dysphagia (091316)
•       9.13.17: Pre-thickened drinks
•       9.13.17.1: Dysphagia (091317)
•       9.13.18: Ketogenic diet
•       9.13.18.1: Intractable epilepsy / GLUT1 deficiency (091318)
•       9.13.19: Inherited metabolic disorder - Carbohydrate source
•       9.13.19.1: Glucose plus galactose intolerance (091319)
•       9.13.19.2: Glycogen storage disease (091319)
•       9.13.19.3: Sucrase-isomaltase deficiency (091319)
•       9.13.20: Inherited metabolic disorder - Protein source
•       9.13.20.1: Homocystinuria (091320)
•       9.13.20.2: Homocystinuria or hypermethioninaemia (091320)
•       9.13.20.3: Methylmalonic or propionic acidaemia (091320)
•       9.13.20.4: MSUD (091320)
•       9.13.20.5: PKU (091320)
•       9.13.20.6: Tyrosinaemia (091320)
•       9.13.20.7: Urea cycle disorders (091320)
•       9.13.20.9: Glutaric aciduria Type 1 (091320)
•       9.13.21: Inherited metabolic disorder - Macronutrient source
•       9.13.21.1: Non condition specific energy source (091321)
•       9.13.21.2: Non condition specific fat source (091321)
•       9.13.21.3: Non condition specific protein source (091321)
•       9.13.22: Inherited metabolic disorder - Protein source (paed)
•       9.13.22.1: Glutaric aciduria Type 1 (091322)
•       9.13.22.2: Homocystinuria (091322)
•       9.13.22.3: Isovaleric acidaemia (091322)
•       9.13.22.4: Methylmalonic or propionic acidaemia (091322)
•       9.13.22.5: MSUD (091322)
•       9.13.22.6: PKU (091322)
•       9.13.22.7: Tyrosinaemia (091322)
•       9.13.23: Inherited metabolic disorder - Protein source (infant)
•       9.13.23.1: Glutaric aciduria Type 1 (091323)
•       9.13.23.2: Homocystinuria (091323)
•       9.13.23.3: Hyperlisinaemia (091323)
•       9.13.23.4: Isovaleric acidaemia (091323)
•       9.13.23.5: Methylmalonic or propionic acidaemia (091323)
•       9.13.23.6: MSUD (091323)
•       9.13.23.7: PKU (091323)
•       9.13.23.8: Tyrosinaemia (091323)
•       9.13.24: Inherited metabolic disorder - Carbohydrate source (infant)
•       9.13.24.2: Glucose plus galactose intolerance (091324)
•       9.13.25: Inherited metabolic disorder - Fat source (infant)
•       9.13.25.1: Lipid metabolism disorders (091325)
•       9.13.26: Food - Low protein
•       9.13.26.1: Inherited metabolic disorder (protein) (091326)
•       9.13.27: Food - Gluten free
•       9.13.27.1: Coeliac disease or dermatitis herpetiformis (091327)
•       9.13.28: Vit & min supplement - Condition specific
•       9.13.28.1: Age related macular degeneration (091328)
•       9.13.28.2: Cystic fibrosis (091328)
•       9.13.28.4: Restrictive therapeutic diet (091328)
•       9.13.29: Vit & min supplement - Condition specific (paed)
•       9.13.29.1: Restrictive therapeutic diet (091329)
•       9.13.30: Flavour additive
•       9.13.30.1: UtM nutrit need using food + unflav imp GI func SPR (091330)
•       9.13.30.2: Add for protein SfI metabolic condition (091330)
•       9.13.31: Non-ACBS ONS
•       9.13.31.1: Unable to meet nutritional needs using food alone (091331)
•       9.13.32: Non-ACBS impaired GI function specific ONS
•       9.13.32.1: Induction of clinical remission in Crohns disease (091332)
•       9.13.33: Non-ACBS renal failure specific ONS
•       9.13.33.1: UtM nutrit needs using food alone + renal failure (091333)
•       9.13.34: Non-ACBS condition specific ONS
•       9.13.34.1: Preparation for surgery (091334)
•       9.13.34.2: Unable to meet nutritional needs using food alone (091334)
•       9.13.35: Non-ACBS condition specific complete infant formula
•       9.13.35.1: Cows milk protein allergy (091335)
•       9.13.35.2: Lactose intolerance (091335)
•       9.13.35.3: Lactose intol, cows milk protein allergy or galact (091335)
•       9.13.35.4: Malabsorption (091335)
•       9.13.35.5: Severe cows milk protein allergy / multiple f/aller (091335)
•       9.13.35.6: Significant reflux (091335)
•       9.13.36: Non-ACBS condition specific follow on formula
•       9.13.36.1: Severe cows milk protein allergy / multiple f/aller (091336)
•       9.13.37: Non-ACBS condition specific complete follow on formula
•       9.13.37.1: Malabsorption (091337)
•       9.13.38: Non-ACBS condition specific complete infant formula
•       9.13.38.1: Infants born at <34 w/gest + weight <2kg + not bfed (091338)
•       9.13.39: Non-ACBS energy and protein fortifier
•       9.13.39.1: Additional energy & protein requirement (091339)
•       9.13.39.2: Additional energy requirement (091339)
•       9.13.40: Non-ACBS fibre fortifier
•       9.13.40.1: Additional fibre requirement (091340)
•       9.13.41: Non-ACBS thickener
•       9.13.41.1: Dysphagia (091341)
•       9.13.42: Non-ACBS pre-thickened drinks
•       9.13.42.1: Dysphagia (091342)
•       9.13.43: Non-ACBS ketogenic diet
•       9.13.43.1: Intractable epilepsy / GLUT1 deficiency (091343)
•       9.13.44: Non-ACBS macronutrient SfI metabolic condition
•       9.13.44.1: Glucose plus galactose intolerance (091344)
•       9.13.44.2: Glutaric aciduria Type 1 (091344)
•       9.13.44.4: Lipid metabolism disorders (091344)
•       9.13.44.5: Non condition specific (091344)
•       9.13.44.6: PKU (091344)
•       9.13.44.7: Sulphite oxidase insufficiency (091344)
•       9.13.44.8: Sucrase-isomaltase def OR Glycogen storage disease (091344)
•       9.13.44.9: Phosphomannose isomerase deficiency (091344)
•       9.13.45: Non-ACBS low protein food
•       9.13.45.1: Inherited metabolic disorder (protein) (091345)
•       9.13.46: Non-ACBS gluten free food
•       9.13.46.1: Coeliac disease or dermatitis hepetiformis (091346)
•       9.13.47: Non-ACBS condition specific vitamin & mineral supplement
•       9.13.47.1: Additional requirement for fat soluble vitamins (091347)
•       9.13.47.2: Age related macular degeneration (091347)
•       9.13.47.3: Cystic fibrosis (091347)
•       9.13.48: Non ACBS oil
•       9.13.48.1: Adrenoleukodystrophy or ALD (091348)
•       9.13.49: Non-ACBS milk replacer
•       9.13.49.1: Personal choice (091349)
•       9.13.50: Non-ACBS infant formulae
•       9.13.50.1: Personal choice (091350)
•       9.13.51: Non-ACBS follow on formula
•       9.13.51.1: Personal choice (091351)
•       9.13.52: Non-ACBS weight loss aid
•       9.13.52.1: Overweight / obesity (091352)
•       9.13.53: Non-ACBS probiotic
•       9.13.53.1: Personal choice (091353)
•       9.13.54: Non-ACBS glucose for diabetic hypo treatment
•       9.13.54.1: Diabetic hypo (091354)
•       9.13.55: Non-ACBS dietary supplement for early alzheimers disease
•       9.13.55.1: Early alzheimers disease (091355)
•       9.13.57: Non-ACBS macronutrient SfI metabolic condition (infant)
•       9.13.57.1: Non ketotic hyperglycinaemia (091357)
•       9.13.57.2: Tyrosinaemia (091357)
•       9.13.60: Non-ACBS reduced fat food
•       9.13.60.1: Personal choice (091360)
•       9.13.62: Non-ACBS Inherited metabolic disorder - Protein source
•       9.13.62.1: PKU (091362)
•       9.13.63: Non-ACBS ONS - Cancer specific
•       9.13.63.1: UtM nutritional needs using food alone + cancer (091363)
•       9.13.65: Human milk fortifier - Premature
•       9.13.65.1: Infants born <34 w/gest+weight <1.5kg + breastfed (091365)
•       9.13.66: Non-ACBS Infant formula - Condition specific
•       9.13.66.1: Cows milk protein allergy + impaired GI func/malab (091366)
•       9.13.67: Non ACBS ONS - Dysphagia specific
•       9.13.67.1: UtM nutritional needs using food alone+dysphagia (091367)
•    9.14: Enteral nutrition
•       9.14.1: Tube feed - Standard
•       9.14.1.1: Feeding tube in situ (091401)
•       9.14.2: Tube feed - Standard (paed)
•       9.14.2.1: Feeding tube in situ (091402)
•       9.14.3: Tube feed - Condition specific
•       9.14.3.1: Feeding tube in situ + fat malabsorption (091403)
•       9.14.3.2: Feeding tube in situ + impaired GI function/malab (091403)
•       9.14.3.3: Feeding tube in situ + non milk based feed required (091403)
•       9.14.3.4: Feeding tube in situ + critically ill (091403)
•       9.14.3.5: Feeding tube in situ + renal failure (091403)
•       9.14.4: Tube feed - Condition specific (paed)
•       9.14.4.1: Feeding tube in situ + impaired GI function/malab (091404)
•       9.14.5: Tube feed - Fortifier condition specific
•       9.14.5.1: Feeding tube in situ+additional protein requirement (041405)
•       9.14.5.2: Feeding tube in situ + additional fibre requirement (041505)
•       9.14.6: Non ACBS tube feed
•       9.14.6.1: Feeding tube in situ (091406)
•       9.14.7: Non-ACBS condition specific tube feed
•       9.14.7.1: Feeding tube in situ (091407)
•       9.14.7.2: Feeding tube in situ + fat malabsorption (091407)
•       9.14.8: Non ACBS condition specific tube feed fortifier
•       9.14.8.1: Feeding tube in situ+additional protein requirement (091408)
• 10: Musculoskeletal and Joint Diseases
•    10.1: Drugs used in rheumatic diseases and gout
•       10.1.1: Non-steroidal anti-inflammatory drugs
•       10.1.1.0: Non-steroidal anti-inflammatory drugs
•       10.1.2: Corticosteroids
•       10.1.2.2: Local corticosteroid injections
•       10.1.3: Rheumatic disease suppressant drugs
•       10.1.3.0: Rheumatic disease suppressant drugs
•       10.1.4: Gout and cytotoxic induced hyperuicaemia
•       10.1.4.0: Gout and cytotoxic induced hyperiuicaemia
•       10.1.5: Other drugs for rheumatic diseases
•       10.1.5.0: Other drugs for rheumatic diseases
•    10.2: Drugs used in neuromuscular disorders
•       10.2.1: Drugs which enhance neuromuscular transmission
•       10.2.1.0: Drugs which enhance neuromuscular transmission
•       10.2.2: Skeletal muscle relaxants
•       10.2.2.0: Skeletal muscle relaxants
•    10.3: Drugs for soft-tissue disorders and topical pain relief
•       10.3.1: Enzymes
•       10.3.1.0: Enzymes
•       10.3.2: Rubefacients, topical NSAIDs, capsaicin and poultices
•       10.3.2.0: Rubefacients, topical NSAIDS, capsaicin and poultice
• 11: Eye
•    11.3: Anti-infective eye preparations
•       11.3.1: Antibacterials
•       11.3.1.0: Antibacterials
•       11.3.2: Antifungals
•       11.3.2.0: Antifungals
•       11.3.3: Antivirals
•       11.3.3.0: Antivirals
•    11.4: Corticosteroids and other anti-inflammatory preparations
•       11.4.1: Corticosteroids
•       11.4.1.0: Corticosteroids
•       11.4.2: Other anti-inflammatory preparations
•       11.4.2.0: Other anti-inflammatory preparations
•    11.5: Mydriatics and cycloplegics
•    11.6: Treatment of glaucoma
•    11.7: Local anaesthetics
•    11.8: Miscellaneous ophthalmic preparations
•       11.8.1: Tear deficiency, eye lubricant and astringent
•       11.8.1.0: Tear deficiency, eye lubricant/astringent
•       11.8.2: Ocular diagnostic & peri-operative prepn & photodynamic tt
•       11.8.2.0: Ocular diagnostic & peri-operative prepn & photodynamic tt
•       11.8.3: Other eye preparations
•       11.8.3.0: Other eye preparations
• 12: Ear, Nose and Oropharynx
•    12.1: Drugs acting on the ear
•       12.1.1: Otitis externa
•       12.1.1.0: Otitis externa
•       12.1.3: Removal of ear wax and other substances
•       12.1.3.0: Removal of ear wax and other substances
•    12.2: Drugs acting on the nose
•       12.2.1: Drugs used in nasal allergy
•       12.2.1.0: Drugs used in nasal allergy
•       12.2.2: Topical nasal decongestants
•       12.2.2.0: Topical nasal decongestants
•       12.2.3: Nasal preparations for infection
•       12.2.3.0: Nasal preparations for infection
•    12.3: Drugs acting on the oropharynx
•       12.3.1: Drugs for oral ulceration and inflammation
•       12.3.1.0: Drugs for oral ulceration and inflammation
•       12.3.2: Oropharyngeal anti-infective drugs
•       12.3.2.0: Oropharyngeal anti-infective drugs
•       12.3.3: Lozenges and sprays
•       12.3.3.0: Lozenges and sprays
•       12.3.4: Mouth-washes, gargles and dentifrices
•       12.3.4.0: Mouth-washes, gargles and dentifrices
•       12.3.5: Treatment of dry mouth
•       12.3.5.0: Treatment of dry mouth
• 13: Skin
•    13.1: Management of skin conditions
•       13.1.1: Management of skin conditions
•       13.1.1.0: Vehicles
•    13.2: Emollient and barrier preparations
•       13.2.1: Emollients
•       13.2.1.0: Emollients
•       13.2.1.1: Emollient bath and shower preparations
•       13.2.2: Barrier preparations
•       13.2.2.0: Barrier preparations
•       13.2.3: Dusting-powders
•       13.2.3.0: Dusting-powders
•    13.3: Topical local anaesthetics and antipruritics
•    13.4: Topical corticosteroids
•    13.5: Preparations for eczema and psoriasis
•       13.5.1: Preparations for eczema
•       13.5.1.0: Preparations for eczema
•       13.5.2: Preparations for psoriasis
•       13.5.2.0: Preparations for psoriasis
•       13.5.3: Drugs affecting the immune response
•       13.5.3.0: Drugs affecting the immune response
•    13.6: Acne and rosacea
•       13.6.1: Topical preparations for acne
•       13.6.1.0: Topical preparations for acne
•       13.6.2: Oral preparations for acne
•       13.6.2.0: Oral preparations for acne
•       13.6.3: Topical preparation for rosacea
•       13.6.3.0: Topical preparation for rosacea
•    13.7: Preparations for warts and calluses
•    13.8: Sunscreens and camouflagers
•       13.8.1: Sunscreening preparations
•       13.8.1.0: Sunscreening preparations
•       13.8.2: Camouflagers
•       13.8.2.0: Camouflagers
•    13.9: Shampoos and other preparations for scalp and hair conditions
•    13.10: Anti-infective skin preparations
•       13.10.1: Antibacterial preparations
•       13.10.1.1: Antibacterial preparations only used topically
•       13.10.1.2: Antibacterial preparations also used systemically
•       13.10.2: Antifungal preparations
•       13.10.2.0: Antifungal preparations
•       13.10.3: Antiviral preparations
•       13.10.3.0: Antiviral preparations
•       13.10.4: Parasiticidal preparations
•       13.10.4.0: Parasiticidal preparations
•       13.10.5: Preparations for minor cuts and abrasions
•       13.10.5.0: Preparations for minor cuts and abrasions
•    13.11: Skin cleansers,antiseptics and desloughing agents
•       13.11.1: Alcohols and saline
•       13.11.1.0: Alcohols and saline
•       13.11.2: Chlorhexidine salts
•       13.11.2.0: Chlorhexidine salts
•       13.11.3: Cationic surfactants and soaps
•       13.11.3.0: Cationic surfactants and soaps
•       13.11.4: Chlorine and iodine
•       13.11.4.0: Chlorine and iodine
•       13.11.5: Phenolics
•       13.11.5.0: Phenolics
•       13.11.6: Oxidisers and dyes
•       13.11.6.0: Oxidisers and dyes
•       13.11.7: Desloughing agents
•       13.11.7.0: Desloughing agents
•    13.12: Antiperspirants
•    13.13: Wound management products
•       13.13.1: Medicated stockings
•       13.13.1.0: Medicated stockings
•       13.13.8: Gel and colloid dressings
•       13.13.8.0: Gel and colloid dressings
•    13.14: Topical circulatory preparations
•    13.15: Miscellaneous topical preparations
• 14: Immunological Products and Vaccines
•    14.3: Diagnostic vaccines
•    14.4: Vaccines and antisera
•    14.5: Immunoglobulins
•       14.5.1: Normal immunoglobulin
•       14.5.1.0: Normal immunoglobulin
•       14.5.2: Disease-specific immunoglobulins
•       14.5.2.0: Disease-specific immunoglobulins
•       14.5.3: Anti-D (Rho) immunoglobulin
•       14.5.3.0: Anti-D (Rho) immunoglobulin
• 15: Anaesthesia
•    15.1: General anaesthesia
•       15.1.1: Intravenous anaesthetics
•       15.1.1.0: Intravenous anaesthetics
•       15.1.2: Inhalational anaesthetics
•       15.1.2.0: Inhalational anaesthetics
•       15.1.3: Antimuscarinic drugs
•       15.1.3.0: Antimuscarinic drugs
•       15.1.4: Sedative and analgesic peri-operative drgs
•       15.1.4.1: Benzodiazepines
•       15.1.4.2: Non-opioid analgesics
•       15.1.4.3: Opioid analgesics
•       15.1.5: Neuromuscular blocking drugs
•       15.1.5.0: Neuromuscular blocking drugs
•       15.1.6: Anticholinesterases used in anaesthesia
•       15.1.6.0: Anticholinesterases used in anaesthesia
•       15.1.7: Antagonists for respiratory depression
•       15.1.7.0: Antagonists for respiratory depression
•    15.2: Local anaesthesia
•       15.2.1: Local anaesthetics
•       15.2.1.0: Local anaesthetics
• 18: Preparations used in Diagnosis
•    18.3: X-Ray contrast media
• 19: Other Drugs and Preparations
•    19.1: Alcohol, wines and spirits
•    19.2: Selective preparations
•       19.2.1: Individually formulated preparations bought in
•       19.2.1.0: Individually formulated preparations bought in
•       19.2.2: Individually formulated preparations prepared extemp
•       19.2.2.0: Individually formulated preparations prepared extemp
•       19.2.3: Homeopathic preparations
•       19.2.3.0: Homeopathic preparations
•       19.2.5: Household and other over the counter lines
•       19.2.5.0: Household and other over the counter lines
•       19.2.5.5: Toiletries
•       19.2.7: Poisoning antidotes
•       19.2.7.0: Poisoning antidotes
•    19.4: Single substances
•    19.5: Other preparations
•    19.6: Acids
•       19.6.1: Concentrated waters
•       19.6.1.0: Concentrated waters
•       19.6.3: Extracts
•       19.6.3.0: Extracts
•       19.6.5: Oils
•       19.6.5.0: Oils
•       19.6.6: Tinctures
•       19.6.6.0: Tinctures
•       19.6.7: Syrups
•       19.6.7.0: Syrups
•    19.7: Base,diluent, suspending agents and stabilisers
•    19.8: Colouring,flavouring and sweetening agents
•    19.9: Disinfectants, preservatives and sterilising agents
•    19.13: Cordials and soft drinks
•    19.14: Waters
•       19.14.1: Sterile water
•       19.14.1.0: Sterile water
•       19.14.2: Purified water
•       19.14.2.0: Purified water
•    19.15: Other gases
• 20: Dressings
•    20.1: Absorbent Cottons
•    20.2: Arm Sling/Bandages
•    20.3: Wound Management & Other Dressings
•    20.4: Gauzes & Gauze Tissue
•    20.5: Tracheostomy & Laryngectomy Appliances
•    20.6: Foam
•    20.7: Lints
•    20.8: Plasters
•    20.9: Stockinette
•    20.10: Surgical Adhesive Tape
•    20.11: Surgical Sutures
•    20.12: Swabs
•    20.13: Unspecified Dressing
•    20.14: Skin Closure Strips, Sterile
•    20.15: Skin Adhesive, Sterile
•    20.16: Tapeless Holders
•    20.17: Cervical Collar
•    20.18: Cellulose Wadding BP 1988
•    20.20: Silk Garments
• 21: Appliances
•    21.1: Other Appliances
•    21.2: Catheters
•    21.3: Chiropody Appliances
•    21.4: Contraceptive Devices
•    21.5: Suprapubic Appliances
•    21.6: Trusses
•    21.7: Elastic Hosiery
•    21.8: Oxygen Masks
•    21.9: Special Sanction Authorisations
•    21.10: C.A.P.D. Administration Equipment
•    21.11: Special Authorisation Guernsey
•    21.12: Peak Flow Meters
•    21.13: Catheter Maintenance Products
•    21.14: Lubricant Gels
•    21.16: Irrigation Solutions
•    21.17: Nasal Device
•    21.18: Vacuum Pumps for Erectile Dysfunction
•    21.19: Oral Film Forming Agents
•    21.20: Venous Ulcer Compression System
•    21.21: Dry Mouth Products
•    21.22: Emollients
•    21.23: Vaginal Moisturisers
•    21.24: Nasal Products
•    21.25: Vaginal Dilators
•    21.26: Leg Ulcer Wrap
•    21.27: Lymphoedema Garments
•    21.28: Anal Irrigation System
•    21.29: Pressure Offloading Device
•    21.30: Eye Products
•    21.31: Cycloidal Vibration Accessories
•    21.32: Inhalation Solutions
•    21.33: Indwelling Pleural Cath Drain System
•    21.34: Vaginal PH Correction Products
•    21.35: Acne Treatment
•    21.36: Adhesive Dressing Remover Ster Silicone
•    21.37: Pelvic Toning Devices
•    21.38: Low Friction Products
•    21.39: Prosthetic Adhesives
•    21.40: Bacterial Decolonisation Products
•    21.41: Debridement Device
•    21.42: Jaw Rehabilitation Device
•    21.43: Micro-Enema - Sodium Citrate
•    21.44: Debrisoft pad 13cm x 20cm
•    21.45: Douches
•    21.46: Hernia Support Garments
•    21.47: Dev For Fungal Nail Infections
•    21.48: Detection Sensor Interstitial Fluid/Gluc
•    21.49: Pulsed Electromagnetic Stimulator
• 22: Incontinence Appliances
•    22.2: Anal Plugs
•    22.5: Catheter Valves
•    22.10: Drainable Dribbling Appliances
•    22.15: Faecal Collectors
•    22.20: Incontinence Belts
•    22.30: Incontinence Sheaths
•    22.40: Incontinence Sheath Fixing Strips & Adh
•    22.50: Leg Bags
•    22.60: Night Drainage Bags
•    22.70: Suspensory Systems
•    22.80: Tubing And Accessories
•    22.85: Insert For Female Stress Incont
•    22.90: Urinal Systems
• 23: Stoma Appliances
•    23.5: Adhesive Discs/Rings/Pads/Plasters
•    23.10: Adhesive (Pastes/Sprays/Solutions)
•    23.15: Adhesive Removers (Sprays/Liquids/Wipes)
•    23.20: Bag Closures
•    23.25: Bag Covers
•    23.30: Belts
•    23.35: Colostomy Bags
•    23.40: Colostomy Sets
•    23.45: Deodorants
•    23.46: Discharge Solidifying Agents
•    23.50: Filters/Bridges
•    23.55: Flanges
•    23.60: Ileostomy Bags
•    23.65: Ileostomy Sets
•    23.70: Irrigation Washout Appliances
•    23.75: Pressure Plates/Shields
•    23.80: Skin Fillers And Protectives
•    23.85: Skin Protectors
•    23.90: Stoma Caps/Dressings
•    23.92: Tubing & Accessories
•    23.93: Accessories (Guernsey)
•    23.94: Two Piece Ostomy Systems
•    23.96: Urostomy Bags
•    23.98: Urostomy Sets
•    23.99: Ostomy Appliances R/Sub Allowed Pre 1985